CDK inhibitor shows promise for inflammatory kidney disease

Drug Discovery Today

Volumn 7, Issue 15, 2002, Pages 789-790

  Clough, Joanne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; MATRIX PROTEIN; ROSCOVITINE; STEROID; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR;

CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG SAFETY; GLOMERULONEPHRITIS; HAIR LOSS; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY SCAR; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PODOCYTE; SHORT SURVEY; TUMOR XENOGRAFT; ARTICLE; DRUG ANTAGONISM; DRUG DESIGN; KIDNEY DISEASE;

CYCLIN-DEPENDENT KINASES; DRUG DESIGN; ENZYME INHIBITORS; GLOMERULONEPHRITIS; HUMAN; INFLAMMATION; KIDNEY DISEASES; HUMANS;

EID: 0036668398     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02392-9     Document Type: Short Survey

References (3)

1. Glomerulonephritis
2. The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis
3. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist